Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Merit Medical (MMSI) to $106 from $117 and keeps an Overweight rating on the shares. The firm notes Merit Medical reported Q1 sales/EPS ahead of consensus and reaffirmed FY25 sales guidance. FY25 EPS outlook is impacted by tariffs and the convert. Merit Medical expects to see a lesser, annualized impact in FY26 due to mitigation strategies, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $106 from $112 at Piper Sandler
- Merit Medical Systems: Strong Performance and Growth Potential Amid Tariff Challenges
- Merit Medical Systems: Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Tariff Challenges
- Merit Medical price target lowered to $108 from $127 at Canaccord
- Merit Medical Reports Strong Q1 2025 Results